|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis.
|
28789393 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
To examine the association between CD44 and c-MET expression in relation to p16 and EGFR in patients with head and neck squamous cell carcinoma (HNSCC).
|
27442811 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
DNA double-strand breaks (DSBs) were assessed by immunofluorescence analysis of 53BP1 foci; DSB levels were determined by neutral comet assay; western blotting was used to evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene expression was examined by real-time polymerase chain reaction; and data from The Cancer Genome Atlas HNSCC project were analyzed. p16 overexpression led to downregulation of TRIP12, which in turn led to increased RNF168 levels, repressed DNA damage repair (DDR), increased 53BP1 foci and enhanced radioresponsiveness.
|
27425591 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma.
|
28975663 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that p16 regulates the invasiveness and metastatic potential of HNSCC cells by impairing angiogenesis.
|
28662664 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall survival after recurrence of HNSCC is influenced by the HNSCC subsite and human papillomavirus or p16 status, as well surgical and systemic interventions.
|
28542679 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patients with the KRAS-variant with HNSCC significantly benefit from the addition of cetuximab to radiotherapy and cisplatin, and there is a significant interaction between the KRAS-variant and p16 status.
|
28006059 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
We detected frequent methylation of p16 (44%), RASSF1A (18%), E-cadherin (53%), H-cadherin (35%), MGMT (35%), DAPK (53%), DCC (42%), COL1A2 (44%), TAC1 (61%), SST (64%), and GALR1 (44%) in HNSCC.
|
27027429 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
307 non-coding transcripts differentially expressed in HNSCC were significantly correlated with patient survival, and associated with mutations in TP53, CDKN2A, CASP8, PRDM9, and FBXW7 and copy number variations in chromosomes 3, 5, 7, and 18.
|
27323410 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma.
|
27105759 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We evaluated serum from 100 patients with known head and neck squamous cell carcinoma (HNSCC) and 50 healthy control patients for 3 previously described methylation targets, endothelin receptor type B (EDNRB), cyclin-dependent kinase inhibitor 2A (CDKN2A or p16), and deleted in colorectal carcinoma (DCC), using quantitative methylation specific polymerase chain reaction (qMSPCR).
|
24995714 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High-risk HPV genotypes and P16INK4a expression in a cohort of head and neck squamous cell carcinoma patients in Singapore.
|
27893418 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Data sources were identification and review of publications assessing survival of the distinct subgroups with both p16 and HPV investigated in HNSCC until February, 2015.
|
26227616 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
CTD_human |
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
|
26909611 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Current techniques for assessing the HPV-16 status in HNSCC include the detection of HPV-16 DNA and p16(INK4a) expression in tumor tissues.
|
26940728 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Human papillomavirus (HPV) type 16 has also been suggested to play a role in etiology of head and neck squamous cell carcinoma (HNSCC). p16 expression is now being used as a surrogate marker of HPV infection in squamous cell carcinoma and provides important prognostic information and future therapy planning.
|
27072243 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The mean age of patients with p16 negative HNSCC was 7 years older than p16 positive disease (Table ).
|
25964135 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
A simultaneous immunocytochemical detection of p16(INK4a) and Ki67 can reliably be performed on liquid-based cytological smears from HNSCC patients using a CINtec PLUS kit.
|
25557267 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Human papillomavirus (HPV), p16 expression, and TP53 mutations are known prognostic factors in head and neck squamous cell carcinoma, but their role in squamous cell carcinoma of the anal canal (SCCAC) is less well established.
|
25871546 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, the data emphasize the urge for further data on HPV-infection in HNSCC to, e.g. clarify to what extent survival benefits of p16INK4A-positive patients are truly attributed to HPV-infections.
|
25310104 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Odds ratio (ORs) and 95% confidence intervals (95%CI) were calculated to evaluate the strength of association between p16INK4a promoter methylation and HNSCC.
|
25835498 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
We here evaluated p16 INK4A as a prognostic marker of treatment response and survival in our SCCHN patients with laryngeal, hypopharyngeal or nasopharyngeal cancers.
|
25640361 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High-grade acute organ toxicity and p16(INK4A) expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma.
|
25575976 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among those HNSCCs that were positive for HR-HPV, 18 (100%) of 18 originated from the oropharynx, whereas only two (13%) of 15 HR-HPV-negative HNSCCs originated from the oropharynx (χ(2) test, P < .05). p16 immunohistochemical assay and HPV 16 in situ hybridization on corresponding histologic specimens were concordant with cytologic HR-HPV results.
|
25873503 |
2015 |